REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Mental illness is thought to be highly prevalent among homeless populations, though access to proper diagnoses is limited. An article written by Lisa Goodman and her colleagues summarized Smith's research into PTSD in homeless single women and mothers in St. Louis, Missouri, which found that 53% of the respondents met diagnostic criteria, and which describes homelessness as a risk factor for mental illness. At least two commonly reported symptoms of psychological trauma, social disaffiliation and learned helplessness are highly prevalent among homeless individuals and families. While mental illness is prevalent, people infrequently receive appropriate care. Case management linked to other services is an effective care approach for improving symptoms in people experiencing homelessness. Case management reduced admission to hospitals, and it reduced substance use by those with substance abuse problems more than typical care.
Vijay Viswanathan is a diabetologist from India who is the chief diabetologist at M.V. Hospital for Diabetes based in Chennai. He is also the President of Prof. M. Viswanathan Diabetes Research Centre and the first Asian President of D-Foot International, a non-profit organization based in Belgium. Viswanathan has published over 543 research papers, in publications including the National Library of Medicine, on topics such as primary prevention and management of diabetes, diabetic foot and prevention of amputation, diabetic nephropathy, socio-economics of diabetes care and Pulmonary TB and diabetes. He has been awarded the Medical Council Award from the Governor of Tamil Nadu at the Tamil Nadu Medical Council in Chennai.
=== CblE type of homocystinuria === Remethylation of homocysteine to methionine by MTR requires the derivative of cobalamin, methylcobalamin. Cobalamin metabolism is initiated by the endocytosis of cobalamin bound to the plasma protein transcobalamin (II). Cleavage of this complex produces free cobalamin, translocating from lysosome to cytoplasm. Conversion can occur to 5'-deoxyadenosylcobalamin (AdoCbl) activating the mitochondrial enzyme methylmalonly coenzyme A mutase or to methylcobalamin (MeCbl). An error in cobalamin metabolism resulting in decreased MeCbl and unaffected AdoCbl is characteristic of the CblE type of homocystinuria. This complementation is rare with autosomal recessive inheritance. The inherited methionine synthase functional deficiency corresponds to a defect in the reducing system required to activate the MTR enzyme. Symptoms of this condition comprise developmental retardation, megaloblastic anemia, homocystinuria, hypomethioninemia, cerebral atrophy and hyperhomocysteinemia. However, hypomethioninemia remains an inconsistent symptom. Decreased MeCbl alongside normal cobalamin uptake is suggestive of decreased intracellular methionine biosynthesis. Occurring mainly in childhood, 15 pathogenic mutations can be associated with CblE type homocystinuria. Additionally, vascular abnormalities are associated with this defect. Impaired reduction of an oxidised cobalt atom in the active site of MTR is associated with this condition, where enzyme activity can be corrected with reducing agents.
== Function == SUMO modification of proteins has many functions. Among the most frequent and best studied are protein stability, nuclear-cytosolic transport, and transcriptional regulation. Typically, only a small fraction of a given protein is SUMOylated and this modification is rapidly reversed by the action of deSUMOylating enzymes. SUMOylation of target proteins has been shown to cause a number of different outcomes including altered localization and binding partners. The SUMO-1 modification of RanGAP1 (the first identified SUMO substrate) leads to its trafficking from cytosol to nuclear pore complex. The SUMO modification of ninein leads to its movement from the centrosome to the nucleus. In many cases, SUMO modification of transcriptional regulators correlates with inhibition of transcription. One can refer to the GeneRIFs of the SUMO proteins, e.g. human SUMO-1, to find out more. There are 4 confirmed SUMO isoforms in humans; SUMO-1, SUMO-2, SUMO-3, and SUMO-4. At the amino acid level, SUMO2 and 3 are nearly identical and cannot be distinguished via antibodies. SUMO1, by contrast, has only 50% similarity with SUMO2. SUMO-4 shows similarity to SUMO-2/3 but differs in having a Proline instead of Glutamine at position 90. As a result, SUMO-4 isn't processed and conjugated under normal conditions, but is used for modification of proteins under stress-conditions like starvation.
== History == MD was originally developed in the early 1950s, following earlier successes with Monte Carlo simulations—which themselves date back to the eighteenth century, in the Buffon's needle problem for example—but was popularized for statistical mechanics at Los Alamos National Laboratory by Marshall Rosenbluth and Nicholas Metropolis in what is known today as the Metropolis–Hastings algorithm. Interest in the time evolution of N-body systems dates much earlier to the seventeenth century, beginning with Isaac Newton, and continued into the following century largely with a focus on celestial mechanics and issues such as the stability of the Solar System. Many of the numerical methods used today were developed during this time period, which predates the use of computers; for example, the most common integration algorithm used today, the Verlet integration algorithm, was used as early as 1791 by Jean Baptiste Joseph Delambre. Numerical calculations with these algorithms can be considered to be MD done "by hand".
Sources: en.wikipedia.org
== N == Robert Nalbandyan (1937–2002), Armenian protein chemist known for discovery of photosynthetic protein plantacyanin Sergey Nametkin (1976–1950), Russian organic chemist known the cracking of petrochemicals, and rearrangement of camphenes Louise Natrajan (PhD 2003), British chemist who ortks on actinide chemistry and luminescence spectroscopy Giulio Natta (1903–1979), Italian chemical engineer worked on high density polymers, 1963 Nobel Prize in Chemistry Costin Nenițescu (1902–1970), Romanian chemist who studied the oxidation of open-chain and aromatic hydrocarbons with chromic acid and chromic oxychloride Antonio Neri (1576–1614), Florentine priest, author of L’Arte Vetraria (The Art of Glass), the first general treatise on the systematics of glassmaking Walther Nernst (1864–1941), German physical chemist whose heat theorem led the way to the third law of thermodynamics, 1920 Nobel Prize in Chemistry John Alexander Reina Newlands (1837–1898), British analytical chemist, precursor of the periodic order of elements William Nicholson (1753–1815), British chemist and civil engineer, the first to achieve electrolysis Kyriacos Costa Nicolaou (born 1946), Cypriot-American chemist known for total synthesis of natural products Julius Nieuwland (1878–1936), Belgian and American prirest and chemist who worked on synthetic rubber Mathias Nilsson, Swedish physical and analytical chemist concerned with liquid NMR spectroscopy Alfred Nobel (1833–1896), Swedish chemist who invented dynamite and established the Nobel Prizes Ronald George Wreyford Norrish (1897–1978), British chemist known for flash photolysis and the Norrish reaction, 1967 Nobel Prize in Chemistry John Howard Northrop (1891–1987), American biochemist known for isolation, crystallization, and study of enzymes, proteins, and viruses; 1946 Nobel Prize in Chemistry Ryōji Noyori (born 1938), Japanese chemist, 2001 Nobel Prize in Chemistry for the study of chirally catalyzed hydrogenations Ralph Nuzzo (born 1954), American materials chemist known for work on the chemistry of materials, including processes that occur at surfaces and interfaces
=== Hypothyroidism === The rate of hypothyroidism is around six times higher in people who take lithium. Low thyroid hormone levels in turn increase the likelihood of developing depression. People taking lithium thus should routinely be assessed for hypothyroidism and treated with synthetic thyroxine if necessary. Lithium associated thyroid dysfunction is reversible and thyroid levels return to normal if lithium is discontinued. However, hypothyroidism can be corrected by treatment with thyroxine and does not require the lithium dose to be adjusted.
== Use and toxicity == The European species did not enter into the herbalists' pharmacopeia. In the American Old West, the Western white clematis, Clematis ligusticifolia, was called pepper vine by early travelers and pioneers, who took a tip from Spanish colonials and used seeds and the acrid leaves of yerba de chivato as a pepper substitute. The entire genus contains essential oils and compounds which are extremely irritating to the skin and mucous membranes. Unlike black pepper or Capsicum, however, the compounds in clematis cause internal bleeding of the digestive tract if ingested in large amounts. C. ligusticifolia is essentially toxic. When pruning them, it is a good idea to wear gloves. Despite its toxicity, Native Americans used very small amounts of clematis as an effective treatment for migraine headaches and nervous disorders. It was also used as an effective treatment of skin infections. Clematis is also a constituent of Bach's Rescue Remedy. Leaf extracts from two Ethiopian species (Clematis longicauda steud ex A. Rich. and Clematis burgensis Engl.) are used locally to treat ear disorders and eczema. Phytochemical screening of the extracts from both of these species showed antibacterial and antifungal activity. The extracts of these plants also possess wound healing and anti-inflammatory activities which could also be attributed to the phytoconstituents. Clematis has been listed as one of the 38 plants used to prepare Bach flower remedies, a kind of alternative medicine promoted for its effect on health.
In this section, the principal GUT models and their variants are briefly introduced, focusing on their proton decay predictions. For a comprehensive overview of Grand Unified Theories, see the dedicated article. SU(5): introduced in 1974 by Georgi and Glashow, is the minimal choice for unification in a simple group. One SM generation of particles comes from
Dehydrogenation by 17β-hydroxysteroid dehydrogenase (17β-HSD) into estrone Conjugation by estrogen sulfotransferases and UDP-glucuronyltransferases into C3 and/or C17β estrogen conjugates like estrone sulfate and estradiol glucuronide Hydroxylation by cytochrome P450 enzymes such as CYP1A1 and CYP3A4 into catechol estrogens like 2-hydroxyestrone and 2-hydroxyestradiol as well as 16-hydroxylated estrogens like 16α-hydroxyestrone and estriol (16α-hydroxyestradiol) The liver is almost entirely responsible for metabolism of estradiol. Both dehydrogenation of estradiol by 17β-HSD into estrone and conjugation into estrogen conjugates are reversible transformations. However, in regards to sulfation and desulfation, transformation of estrone into estrone sulfate is predominant relative to the reverse reaction. Estradiol can also be reversibly converted into long-lived lipoidal estradiol forms like estradiol palmitate and estradiol stearate as a minor route of metabolism. The elimination half-life of estradiol administered via intravenous injection has been found to be 2 hours in men and 27 to 50 minutes in women. Other routes of administration of estradiol like oral administration or intramuscular injection have far longer elimination half-lives and durations of action due to (1) the formation of a large circulating reservoir of metabolism-resistant estrogen conjugates that can be reconverted back into estradiol and/or (2) the formation of slowly-releasing depots.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.